Master the prostate mpMRI protocol with a step-by-step framework covering high-resolution multiplanar T2, high b-value DWI, precisely timed DCE, PI-RADS v2.1 scoring logic, and the scanning, interpretive, and clinical pitfalls that most often undermine accurate clinically significant prostate cancer detection.

Prostate mpMRI Protocol: The Complete Radiographer & Radiologist Guide

Introduction

A rigorously executed prostate mpMRI protocol has transformed the prostate cancer diagnostic pathway from a blind, systematic transrectal ultrasound (TRUS) biopsy model toward targeted, image-guided sampling that detects more clinically significant cancer while reducing overdiagnosis of indolent disease. Multiparametric MRI — the combination of high-resolution T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging — now sits upstream of biopsy in most contemporary pathways, meaning technical quality at acquisition directly determines whether a patient is correctly triaged toward biopsy, active surveillance, or no further action.

Prostate cancer remains one of the most commonly diagnosed cancers in men, and the central diagnostic challenge is not detecting cancer in general but distinguishing clinically significant cancer — disease with genuine metastatic potential warranting treatment — from indolent, low-grade disease that may never require intervention. mpMRI’s role is precisely this triage function, and the PI-RADS (Prostate Imaging Reporting and Data System) framework, covered in detail later in this guide, exists specifically to standardize how that risk is communicated.

This guide walks through the complete prostate mpMRI workflow: the zonal anatomy that dictates sequence planning and PI-RADS scoring logic, relevant relaxation values, a ten-step scanning technique, the DCE protocol, SAR-conscious parameter selection, the top ten pathologies and mimickers the protocol must resolve, a full walkthrough of the PI-RADS v2.1 framework with anatomical and decision-pathway diagrams, a dedicated review of mpMRI’s diagnostic accuracy relative to its individual component sequences, and the distinct pitfalls that affect radiographers at the console, radiologists at the workstation, and referring urologists acting on the report.

Prostate Anatomy Essentials

The prostate is a walnut-sized fibromuscular gland surrounding the proximal urethra, situated inferior to the bladder and anterior to the rectum — a relationship that is both diagnostically useful (the rectal wall provides a natural acoustic/imaging window) and technically hazardous, since rectal gas immediately posterior to the gland is the source of the primary artifact this protocol must manage.

Zonal anatomy

McNeal’s zonal model divides the gland into four regions with distinct cancer risk profiles and distinct baseline imaging appearances. The peripheral zone (PZ) comprises roughly 70% of glandular volume, forms the posterior and lateral aspect of the gland, and is the site of origin of approximately 70–75% of prostate cancers — it is normally uniformly T2 hyperintense, making focal T2 hypointensity a key detection cue. The transition zone (TZ) surrounds the proximal urethra, is the site of benign prostatic hyperplasia (BPH), and has a heterogeneous, nodular baseline T2 appearance that makes cancer detection here considerably harder than in the PZ. The central zone (CZ) surrounds the ejaculatory ducts, is normally T2 hypointense, and rarely harbors primary cancer. The anterior fibromuscular stroma (AFMS) is a non-glandular band anteriorly that is essentially devoid of glandular tissue and therefore an uncommon site of malignancy.

Capsule and neurovascular bundles

The prostate is enclosed by a thin fibrous capsule, and assessment of capsular integrity — smooth versus irregular or frankly disrupted — is central to local staging. The neurovascular bundles run posterolaterally at the 5 and 7 o’clock positions and are a key structure to evaluate for perineural or extracapsular tumor spread, directly relevant to nerve-sparing surgical planning.

Seminal vesicles and rectal relationship

The paired seminal vesicles sit superoposterior to the prostate base and should be specifically assessed for tumor invasion, a T3b staging feature with significant prognostic weight. The gland’s direct apposition to the anterior rectal wall is the anatomic basis of the rectal gas susceptibility artifact central to this protocol’s technical challenges.

MR Tissue Relaxation Values

Understanding baseline T1 and T2 relaxation times of normal prostatic zonal anatomy underpins correct recognition of the focal signal abnormalities PI-RADS scoring depends on.

This profile explains the fundamental PZ detection principle: normal peripheral zone tissue is markedly T2 hyperintense, so a focal, round-to-lenticular area of relatively low T2 signal stands out clearly against this bright background — the basis of PI-RADS T2 scoring in the PZ. In the transition zone, where background signal is already heterogeneous and comparatively lower, this contrast mechanism is far less reliable, which is why PI-RADS designates DWI as the dominant sequence in the PZ but T2W as the dominant sequence in the TZ, discussed fully in the PI-RADS section below.

Scanning Technique — 10 Steps

1. Patient preparation and bowel prep. Administer a rectal micro-enema 1–2 hours before scanning per departmental bowel prep protocol to evacuate rectal gas and stool, the single most impactful preparatory step for image quality in this protocol.
2. Antispasmodic consideration. Some departments administer an antispasmodic (glucagon or Buscopan) to reduce rectal peristalsis; confirm local protocol and contraindications.
3. Coil selection and positioning. Use a torso/pelvic phased-array coil; endorectal coil use varies by institutional preference and is not required at 3T per current consensus guidance, though it remains used selectively at 1.5T.
4. Localizer and coverage planning. Acquire a tri-plane localizer confirming full coverage of the prostate, seminal vesicles, and pelvic sidewalls for nodal assessment.
5. High-resolution multiplanar T2-weighted imaging. Acquire axial, sagittal, and coronal T2 with no interslice gap and small FOV (~14–20 cm), slice thickness ≤3 mm — this sequence forms the anatomical backbone for both PZ and TZ scoring.
6. High b-value DWI. Acquire diffusion-weighted imaging with a calculated or acquired high b-value ≥1400 s/mm² and generate the corresponding ADC map; use fast spin-echo DWI or readout-segmented EPI (RESOLVE) if rectal gas artifact persists despite bowel prep.
7. Pre-contrast axial T1. Acquire a standard axial T1 sequence to assess for post-biopsy hemorrhage, which can confound both T2 and DCE interpretation if unrecognized.
8. DCE dynamic acquisition. Administer the gadolinium bolus and acquire a dynamic T1 series with temporal resolution <15 seconds, continuing for at least 2–5 minutes to characterize early enhancement and washout kinetics.
9. Extended pelvic coverage for staging. Acquire a larger-FOV axial T2 or T1 sequence extending to the pelvic sidewalls and common iliac nodal stations when local staging is clinically indicated.
10. Quality review before release. Confirm DWI/ADC and T2 are well co-registered (minimal geometric distortion), the full gland and seminal vesicles are covered without gap, and DCE temporal resolution was achieved before releasing the patient.

Scanner comparison table (1.5T vs. 3.0T)

Contrast Media Protocol

Dynamic contrast-enhanced imaging is the third pillar of the prostate mpMRI examination, characterizing the early, avid enhancement and washout kinetics characteristic of angiogenically active tumor tissue.

PI-RADS v2.1 designates DCE as a secondary, largely binary parameter (positive or negative for focal early enhancement) rather than an independently scored 1–5 category, and its practical role is narrowly defined: it can upgrade an equivocal PI-RADS 3 peripheral zone lesion on DWI to a PI-RADS 4 if focal, early, and corresponding enhancement is present. This deliberately limited role — discussed further in the accuracy comparison section below — reflects growing evidence that DCE contributes relatively modest incremental diagnostic value once high-quality T2 and DWI are already available, though it remains a required protocol component per current guidance.

Specific Absorption Rate & Dose Reduction

The combination of high-resolution multiplanar T2, high b-value DWI, and rapid-temporal-resolution DCE makes prostate mpMRI a genuinely RF-intensive protocol, particularly at 3T where the DCE series alone can approach SAR ceilings if flip angle and acceleration are not carefully managed.

Five dose reduction strategies

1. Reduce flip angle on the DCE 3D T1 sequence to the minimum required for adequate temporal resolution and SNR, particularly at 3T.
2. Employ parallel imaging on both DWI and DCE sequences to shorten acquisition and reduce total RF pulses.
3. Use fast spin-echo DWI or RESOLVE selectively rather than by default, reserving it for patients with confirmed residual susceptibility distortion, since these techniques carry their own RF cost relative to standard single-shot EPI.
4. Optimize T2 turbo factor to balance spatial resolution against RF duty cycle rather than maximizing resolution indiscriminately.
5. Sequence the protocol thoughtfully, placing the highest-SAR sequences with adequate inter-sequence recovery time built into the overall exam timeline.

Top 10 Pathologies

PI-RADS v2.1: The Complete Framework

The Prostate Imaging Reporting and Data System (PI-RADS) was developed jointly by the American College of Radiology, the European Society of Urogenital Radiology, and the AdMeTech Foundation to standardize the acquisition, interpretation, and reporting of prostate mpMRI. Before PI-RADS, prostate MRI reporting varied enormously between institutions and even between radiologists at the same institution, undermining referring urologists’ confidence in the test and making multi-site research comparison nearly impossible. The current iteration, PI-RADS v2.1, refined the original v2 framework published in 2016, clarifying several genuinely ambiguous scoring rules — particularly around transition zone assessment and DCE’s role — based on several years of accumulated clinical experience and validation data.

The five-point scoring scale

PI-RADS assigns each identified lesion a category from 1 to 5, reflecting the probability that the finding represents clinically significant cancer (generally defined as Gleason score ≥3+4 or a volume ≥0.5 cc). PI-RADS 1 indicates clinically significant cancer is highly unlikely to be present. PI-RADS 2 indicates clinically significant cancer is unlikely. PI-RADS 3 is genuinely equivocal — intermediate risk, neither clearly benign nor clearly suspicious. PI-RADS 4 indicates clinically significant cancer is likely to be present. PI-RADS 5 indicates clinically significant cancer is highly likely to be present. In most contemporary pathways, PI-RADS 4–5 lesions proceed directly to targeted biopsy, PI-RADS 3 lesions are managed with a combination of PSA density, clinical risk factors, and often biopsy, and PI-RADS 1–2 lesions typically do not require biopsy in the absence of other clinical concern.

Dominant sequence logic: why zone matters

The single most important structural concept in PI-RADS v2.1 is that the dominant sequence differs by zone, directly reflecting the anatomical and signal-contrast principles discussed in the anatomy and relaxation-value sections above. In the peripheral zone, DWI is the dominant sequence — the ADC map and high b-value image drive the primary category, since restricted diffusion is a more reliable discriminator than T2 signal alone against the PZ’s uniformly hyperintense background. In the transition zone, T2-weighted imaging is the dominant sequence — morphological features (encapsulation, homogeneity, lenticular versus round shape) drive the primary category, since DWI/ADC changes in the TZ are confounded by the heterogeneous signal of background BPH nodules, which themselves frequently show mild diffusion restriction unrelated to malignancy.

T2W scoring criteria by zone

In the peripheral zone, T2 category assignment ranges from PI-RADS 1 (normal, uniform hyperintense signal) through PI-RADS 3 (heterogeneous signal or non-circumscribed, rounded, mild-to-moderate hypointensity) to PI-RADS 5 (same features as 4 but ≥1.5 cm or with definite extraprostatic extension). In the transition zone, scoring depends heavily on distinguishing a typical, encapsulated BPH nodule (low suspicion) from a lenticular or non-circumscribed, homogeneously moderately hypointense lesion — often described using the “erased charcoal” descriptor — which raises suspicion toward PI-RADS 4–5, particularly with extension beyond the capsule or invasion of the anterior fibromuscular stroma.

DWI/ADC scoring criteria

DWI/ADC scoring in the peripheral zone (where it is dominant) ranges from PI-RADS 1 (no abnormality on ADC/high b-value) through PI-RADS 3 (focal mild/moderate hypointensity on ADC or mild hyperintensity on high b-value, ambiguous) to PI-RADS 5 (focal markedly hypointense ADC and markedly hyperintense high b-value lesion ≥1.5 cm, or with definite extraprostatic extension). The high b-value requirement specified in the protocol above (≥1400 s/mm²) is not arbitrary — lower b-values provide inadequate background signal suppression to reliably distinguish restricted diffusion in small, clinically significant lesions from normal glandular tissue.

Structured reporting and sector maps

PI-RADS reporting is built around a standardized 39-sector prostate map dividing the gland into base, mid-gland, and apex thirds, each further subdivided by zone and laterality. Documenting lesion location using this sector map — rather than free-text description — is essential for accurate MRI-TRUS fusion targeting at biopsy, since even small localization errors can cause a biopsy needle to sample adjacent normal tissue rather than the true lesion, directly undermining the entire targeted-biopsy value proposition that motivates performing mpMRI in the first place.

Sensitivity & Specificity: mpMRI vs. T2W vs. DWI

A frequently asked technical and clinical question is how much diagnostic value each component sequence of the multiparametric protocol actually contributes, and whether the full three-sequence protocol (T2W + DWI + DCE) meaningfully outperforms simpler combinations. This question has direct protocol design implications — DCE requires intravenous contrast, extends scan time, and adds cost and complexity, so understanding its incremental value against T2W and DWI alone is genuinely important for departmental protocol decisions.

The PROMIS trial — a prospective, paired-cohort validating study comparing mpMRI and systematic TRUS biopsy against a combined biopsy reference standard — reported mpMRI sensitivity of 93% and specificity of 41% for clinically significant cancer, compared with systematic TRUS biopsy’s sensitivity of 48% and specificity of 96%.^[2] This trade-off is clinically important to understand correctly: mpMRI’s lower specificity does not mean it produces large numbers of false-positive cancer diagnoses; rather, it means a substantial proportion of PI-RADS 3 or occasionally PI-RADS 4 findings on MRI do not correspond to clinically significant cancer at biopsy. The clinical value proposition instead comes from mpMRI’s high negative predictive performance — a properly acquired PI-RADS 1–2 study allows a meaningful proportion of men to safely avoid biopsy altogether, which was the central finding driving PROMIS’s practice-changing impact.

The subsequent PRECISION trial extended this evidence into a randomized, biopsy-naive population, comparing an MRI-first pathway (with biopsy only for MRI-positive men, targeted to the visible lesion) against standard systematic TRUS biopsy in all men.^[3] The MRI-targeted pathway detected clinically significant cancer in 38% of men versus 26% with standard biopsy, while detecting substantially fewer clinically insignificant cancers (9% vs. 22%) — direct evidence that a well-executed mpMRI protocol does not merely match blind biopsy but measurably improves the ratio of clinically significant to clinically insignificant detection, reducing overdiagnosis alongside improving sensitivity.

The practical implication for protocol design, reflected in PI-RADS v2.1’s structure, is that T2W and DWI together capture the substantial majority of mpMRI’s diagnostic value, with DCE contributing a comparatively narrow — though still clinically meaningful — incremental benefit concentrated in equivocal peripheral zone lesions. Several head-to-head comparisons of biparametric (T2W + DWI) against full triparametric protocols have reported broadly comparable detection rates for PI-RADS ≥3 lesions, which has motivated some centers to explore biparametric protocols in carefully selected populations, primarily to reduce scan time, cost, and gadolinium exposure.^[5] Current PI-RADS v2.1 guidance nonetheless still recommends including DCE as a standard protocol component, given its defined (if narrow) upgrade role and the ongoing accumulation of validating evidence specifically for triparametric protocols relative to the comparatively newer biparametric approach.

Pitfalls — Radiographers

Primary scanning pitfall (from protocol data): Rectal gas susceptibility artifact, most severely affecting EPI-based DWI, resulting from inadequate or omitted bowel preparation before scanning.

Pitfalls — Radiologists

Primary interpretation pitfall (from protocol data): Misregistration between susceptibility-distorted DWI/ADC images and the true anatomic location on T2W, caused by residual rectal gas, leading to incorrect sector localization of a suspicious lesion.

Pitfalls — Non-Radiology Physicians

Pitfall Comparison Summary

AI & Automation in Prostate mpMRI

Automated prostate and lesion segmentation, ADC quantification, and PI-RADS-assistive scoring tools are among the more mature AI applications in body MRI, reflecting the relatively standardized nature of the PI-RADS framework itself. Several CE-marked and FDA-cleared platforms now provide automated gland segmentation, PSA density calculation support, and lesion-level probability scoring intended to flag findings for radiologist review and reduce the inter-reader variability that remains a well-documented limitation of visual PI-RADS scoring, particularly in the transition zone.

These tools function as a structured second check rather than a replacement for radiologist judgment, and their output is most useful precisely where human interpretation is least consistent — equivocal PI-RADS 3 lesions and transition zone assessment — areas directly addressed by the pitfalls discussed above.

Further Reading

1. 5 Male Pelvic CT Protocol Tactics for Radiologists
2. 7 Proven Strategies for Optimizing MRI Sequences in 2026
3. CT Cystography Protocol: 7 Critical Bladder Steps
4. 2026 Contrast Media Guidelines: eGFR Thresholds & Safe Administration Protocol
5. MRCP Pancreas Protocol: 10 Proven Scanning Steps

Reducing Artefacts with Patients and Parameters

The most critical scanning parameters that impact image quality include:

1. Spatial Resolution

Spatial resolution defines the ability to distinguish small details in an image. Matrix Size: Increasing the matrix size (frequency × phase) increases spatial resolution, but decreases SNR because the voxel (3D pixel) size becomes smaller. Field of View (FOV): Reducing the FOV increases spatial resolution. However, smaller FOV results in smaller voxels and reduces SNR. Slice Thickness: Thinner slices provide higher spatial resolution and reduce partial volume averaging, but significantly decrease SNR.

2. Signal-to-Noise Ratio (SNR)

SNR represents the strength of the diagnostic signal relative to inherent background noise. A high SNR produces crisp, clear images, whereas a low SNR looks grainy. Number of Averages (NEX/NSA): Increasing averages acquires data multiple times, which improves SNR. However, doubling the averages roughly doubles the scan time. Receiver Bandwidth: Decreasing the bandwidth limits the amount of noise recorded, boosting SNR. However, a lower bandwidth increases scan times and chemical shift artifacts. Coil Selection: Using dedicated, localized surface coils rather than whole-body coils captures much stronger signals and heavily improves SNR.

3. Image Contrast

Contrast determines how different tissues are distinguished from one another (e.g., highlighting bone vs. fluid vs. muscle). Repetition Time (TR): TR is the time between consecutive RF pulses. A short TR maximizes T1 tissue contrast, while a long TR minimizes it. Echo Time (TE): TE is the time between the RF pulse and the peak of the echo signal. A short TE minimizes T2 effects, and a long TE maximizes T2 weighting, making fluid-filled areas appear very bright. Flip Angle: Controls the excitation of protons. Adjusting the flip angle changes tissue contrast and is especially critical in gradient echo sequences.

4. Artifact Control

Artifacts are visual distortions or ghosting that degrade image quality. Phase Encoding Direction: Swapping the phase and frequency axes can shift motion-induced artifacts (like breathing or blood flow) away from the primary region of interest. Flow Compensation / Gating: Utilizes physiological triggers (e.g., electrocardiogram) to minimize blurring and ghosting caused by pulsatile motion. Parallel Imaging: Utilizes multiple coil elements simultaneously to reduce phase encoding steps, significantly cutting down scan time and reducing motion artifacts.

Parallel Imaging Protocols and Parameters

Parallel imaging acceleration is essential for balancing the high spatial resolution T2 and DWI sequences require against the rapid temporal resolution DCE demands, all within a clinically practical total exam time.

As a general principle: increasing turbo/acceleration factor shortens acquisition and improves temporal resolution but can blur fine zonal and lesion-margin detail — a meaningful concern for the millimeter-scale distinctions PI-RADS scoring depends on, particularly the encapsulation and shape criteria used to separate BPH nodules from transition zone cancer. The optimal balance favors moderate turbo factors on T2W, targeted use of distortion-resistant DWI techniques rather than blanket over-acceleration, and higher acceleration specifically on the time-critical DCE sequence.

Conclusion

A technically sound prostate mpMRI protocol rests on four pillars: disciplined bowel preparation and susceptibility-resistant DWI technique to manage the rectal gas artifact that most directly threatens this protocol’s diagnostic core; a coordinated sequence set — high-resolution T2W, high b-value DWI, and rapidly timed DCE — matched to the zone-specific dominant-sequence logic PI-RADS v2.1 formalizes; a clear-eyed understanding of what the published sensitivity and specificity evidence actually supports, and what it assumes about acquisition quality; and disciplined awareness of the distinct pitfall patterns that affect radiographers at acquisition, radiologists at interpretation, and referring urologists acting on the final report.

From peripheral zone clinically significant cancer through the genuinely difficult transition zone BPH-versus-cancer distinction, the protocol’s diagnostic power — validated at PROMIS and PRECISION trial scale — depends entirely on treating technical execution, standardized PI-RADS scoring, and clinical integration as inseparable parts of a single pathway. Departments that standardize bowel prep, DWI technique selection, and DCE bolus timing consistently produce more actionable, less ambiguous prostate mpMRI reports — sparing patients unnecessary biopsy while ensuring clinically significant disease is not missed.

References

1. Turkbey, B., Rosenkrantz, A. B., Haider, M. A., Padhani, A. R., Villeirs, G., Macura, K. J., Tempany, C. M., Choyke, P. L., Cornud, F., Margolis, D. J., Thoeny, H. C., Verma, S., Barentsz, J., & Weinreb, J. C. (2019). Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. European Urology, 76(3), 340–351. https://doi.org/10.1016/j.eururo.2019.02.033
2. Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., Kirkham, A. P., Oldroyd, R., Parker, C., Emberton, M., & PROMIS study group. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. The Lancet, 389(10071), 815–822. https://doi.org/10.1016/S0140-6736(16)32401-1
3. Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., Roobol, M. J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G. M., Virdi, J., Boxler, S., Robert, G., … PRECISION Study Group Collaborators. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767–1777. https://doi.org/10.1056/NEJMoa1801993
4. Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., Thoeny, H. C., & Verma, S. (2016). PI-RADS Prostate Imaging – Reporting and Data System: 2015, version 2. European Urology, 69(1), 16–40. https://doi.org/10.1016/j.eururo.2015.08.052
5. Israël, B., van der Leest, M., Sedelaar, M., Padhani, A. R., Zámecnik, P., & Barentsz, J. O. (2020). Multiparametric or biparametric prostate MRI: Is DCE always necessary? European Urology, 78(3), 466–467. https://doi.org/10.1016/j.eururo.2020.05.003
6. Fütterer, J. J., Briganti, A., De Visschere, P., Emberton, M., Giannarini, G., Kirkham, A., Taneja, S. S., Thoeny, H., Villeirs, G., & Villers, A. (2015). Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. European Urology, 68(6), 1045–1053. https://doi.org/10.1016/j.eururo.2015.01.013
7. de Rooij, M., Hamoen, E. H., Fütterer, J. J., Barentsz, J. O., & Rovers, M. M. (2014). Accuracy of multiparametric MRI for prostate cancer detection: A meta-analysis. American Journal of Roentgenology, 202(2), 343–351. https://doi.org/10.2214/AJR.13.11046
8. Barentsz, J. O., Weinreb, J. C., Verma, S., Thoeny, H. C., Tempany, C. M., Shtern, F., Padhani, A. R., Margolis, D., Macura, K. J., Haider, M. A., Cornud, F., & Choyke, P. L. (2016). Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. European Urology, 69(1), 41–49. https://doi.org/10.1016/j.eururo.2015.08.038
9. Rosenkrantz, A. B., Ginocchio, L. A., Cornfeld, D., Froemming, A. T., Gupta, R. T., Turkbey, B., Westphalen, A. C., Babb, J. S., & Margolis, D. J. (2016). Interobserver reproducibility of the PI-RADS version 2 lexicon: A multicenter study of six experienced prostate radiologists. Radiology, 280(3), 793–804. https://doi.org/10.1148/radiol.2016152542
10. American College of Radiology. (2023). ACR manual on contrast media (Version 2023). American College of Radiology. acr.org/Clinical-Resources/Contrast-Manual
11. Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019). Prostate Imaging-Reporting and Data System steering committee: PI-RADS v2 status update and future directions. European Urology, 75(3), 385–396. https://doi.org/10.1016/j.eururo.2018.05.035
12. Greer, M. D., Shih, J. H., Lay, N., Barrett, T., Kayat Bittencourt, L., Borofsky, S., Kabakus, I. M., Law, Y. M., Marko, J., Shebel, H., Mertan, F. V., Merino, M. J., Wood, B. J., Pinto, P. A., Choyke, P. L., & Turkbey, B. (2019). Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology, 292(2), 464–474. https://doi.org/10.1148/radiol.2019182828
13. Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., Ruffion, A., Colombel, M., Crouzet, S., Schott, A. M., Lemaitre, L., Rabilloud, M., Grenier, N., & MRI-FIRST investigators. (2019). Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study. The Lancet Oncology, 20(1), 100–109. https://doi.org/10.1016/S1470-2045(18)30569-2
14. van der Leest, M., Cornel, E., Israël, B., Hendriks, R., Padhani, A. R., Hoogenboom, M., Zamecnik, P., Bakker, D., Setiasti, A. Y., Veltman, J., van den Hout, H., van der Lelij, H., van Oort, I., Klaver, S., Debruyne, F., Sedelaar, M., Hannink, G., Rovers, M., Hulsbergen-van de Kaa, C., & Barentsz, J. O. (2019). Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen. European Urology, 75(4), 570–578. https://doi.org/10.1016/j.eururo.2018.11.023
15. Drost, F. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019). Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 4(4), CD012663. https://doi.org/10.1002/14651858.CD012663.pub2
16. Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., & Kim, S. H. (2017). Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: A systematic review and meta-analysis. American Journal of Roentgenology, 211(5), W226–W241. https://doi.org/10.2214/AJR.18.19880
17. Purysko, A. S., Bittencourt, L. K., Bullen, J. A., Mostardeiro, T. R., Herts, B. R., & Klein, E. A. (2017). Accuracy and interobserver agreement for PI-RADS version 2, in the diagnosis and staging of prostate cancer. American Journal of Roentgenology, 209(2), 339–349. https://doi.org/10.2214/AJR.16.17289
18. Sathianathen, N. J., Omer, A., Harriss, E., Davies, L., Kasivisvanathan, V., Punwani, S., Moore, C. M., Kastner, C., Barrett, T., Van den Bergh, R. C. N., Eddy, B., Gleeson, F., & Bryant, R. J. (2020). Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the PROMIS and PRECISION trials: A systematic review and meta-analysis. European Urology, 78(3), 402–414. https://doi.org/10.1016/j.eururo.2020.03.048
19. Schoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. M. (2015). Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: A systematic review and meta-analysis. European Urology, 68(3), 438–450. https://doi.org/10.1016/j.eururo.2014.11.037
20. Thörmer, G., Otto, J., Reiss-Zimmermann, M., Seiwerts, M., Moche, M., Garnov, N., Franz, T., Do, M., Stolzenburg, J. U., Horn, L. C., Kahn, T., & Busse, H. (2015). Diagnostic value of ADC in patients with prostate cancer: Influence of the imaging plane and readout direction on ADC values. European Radiology, 25(2), 337–345. https://doi.org/10.1007/s00330-014-3417-z
21. Rosenkrantz, A. B., Chandarana, H., Hindman, N., Deng, F. M., Babb, J. S., Taneja, S. S., & Geppert, C. (2013). Computed diffusion-weighted imaging of the prostate at 3 T: Impact on image quality and tumour detection. European Radiology, 23(11), 3170–3177. https://doi.org/10.1007/s00330-013-2917-6
22. Attenberger, U. I., Rathmann, N., Sertdemir, M., Riffel, P., Weidner, A., Kannengiesser, S., Morelli, J. N., Schoenberg, S. O., & Hausmann, D. (2016). Multi-parametric MRI of the prostate: Reduction of readout-segmented echo-planar imaging related distortion artifacts. European Journal of Radiology, 85(10), 1740–1747. https://doi.org/10.1016/j.ejrad.2016.07.014
23. European Society of Urogenital Radiology. (2018). ESUR guidelines on contrast agents (Version 10.0). ESUR. esur.org/esur-guidelines-on-contrast-agents
24. Levin, A., & Stevens, P. E. (2024). Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4), 684–701. https://doi.org/10.1016/j.kint.2023.10.016
25. International Commission on Radiological Protection. (2020). ICRP publication 147: Use of dosimetric quantities for regulatory purposes. ICRP. icrp.org/publication.asp?id=ICRP Publication 147
26. SATMED Health. (2026, May 31). 7 proven strategies for optimizing MRI sequences in 2026. https://www.satmed-health.com/optimizing-mri-sequences/
27. SATMED Health. (2026, March 1). 2026 contrast media guidelines: eGFR thresholds & safe administration protocol. https://www.satmed-health.com/2026-worldwide-guidelines…
28. Verma, S., Turkbey, B., Muradyan, N., Rajesh, A., Cornud, F., Haider, M. A., Choyke, P. L., & Harisinghani, M. (2012). Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. American Journal of Roentgenology, 198(6), 1277–1288. https://doi.org/10.2214/AJR.12.8510
29. Hansford, B. G., Peng, Y., Jiang, Y., Vannier, M. W., Antic, T., Thomas, S., Giannini, J., Sammet, S., Oto, A. (2015). Dynamic contrast-enhanced MR imaging curve-type analysis: Is it helpful in the differentiation of prostate cancer from healthy peripheral zone? Radiology, 275(2), 448–457. https://doi.org/10.1148/radiol.14140847
30. Cuocolo, R., Cipullo, M. B., Stanzione, A., Ugga, L., Romeo, V., Radice, L., Brunetti, A., & Imbriaco, M. (2019). Machine learning applications in prostate cancer magnetic resonance imaging. European Radiology Experimental, 3(1), 35. https://doi.org/10.1186/s41747-019-0109-2